Skip to main content
logo
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.160
-0.010 (-0.85%)
Oct 8, 2026, 11:01 AM EDT - Market open

Spero Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4766.847.98103.7853.5118.26
Revenue Growth
-3.25%39.24%-53.77%93.95%193.10%95.67%
Gross Profit
26.4728.34-48.7852.345.92-46.27
Operating Income
6.617.16-72.4826.79-30.57-87.97
Net Income
7.388.57-68.5722.81-46.42-89.76
Earnings Per Share
0.130.15-1.270.43-1.23-2.91
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
50.7740.2752.8976.33109.11146.4
Total Debt
2.042.94.35.546.6555.75
Net Cash (Debt)
48.7337.3748.5970.79102.4690.65
Net Cash Growth
76.70%-23.09%-31.36%-30.91%13.02%-23.86%
Net Cash Per Share
0.810.630.901.342.732.93

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
19.58-12.62-23.44-33-7.73-64.35
Capital Expenditures
------
Free Cash Flow
19.58-12.62-23.44-33-7.73-64.35
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
56.31%42.42%-101.67%50.43%11.06%-253.45%
Operating Margin
14.07%10.72%-151.08%25.81%-57.13%-481.87%
Pretax Margin
16.26%13.22%-142.91%24.48%-86.74%-491.65%
Profit Margin
15.71%12.83%-142.91%21.98%-86.74%-491.65%
FCF Margin
41.66%-18.90%-48.86%-31.79%-14.45%-352.47%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
9.1615.31-3.42--
Forward PE
-4.88----
PS Ratio
1.451.971.170.751.6728.35